Acadia Pharmaceuticals reported a successful third quarter in 2024, with total revenues of $250.4 million, reflecting an 18% increase year-over-year. The company is on track to achieve over $1 billion in annualized sales in 2025, driven by the growth of NUPLAZID and DAYBUE.
Total revenues reached $250.4 million, an 18% increase compared to the third quarter of 2023.
NUPLAZID net product sales were $159.2 million, representing a 10% year-over-year increase.
DAYBUE net product sales amounted to $91.2 million, a 36% increase compared to the same period last year.
Net income for the quarter was $32.8 million, or $0.20 per common share, a significant improvement from the net loss of $65.2 million in the third quarter of 2023.
Acadia is updating its 2024 guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance